A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 1872 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Estimated Study Start Date: August 1, 2019
Estimated Primary Completion Date: March 23, 2021
Estimated Study Completion Date: April 23, 2021
Arms
- Experimental: 5 mg Tirzepatide
- Experimental: 10 mg Tirzepatide
- Experimental: 15 mg Tirzepatide
- Active Comparator: Semaglutide
| Category | Value |
|---|---|
| Date last updated at source | 2019-07-03 |
| Study type(s) | Interventional |
| Expected enrolment | 1872 |
| Study start date | 2019-08-01 |
| Estimated primary completion date | 2021-03-23 |